Systematic Review ARTICLE
C-Reactive Protein as a Peripheral Biomarker in Schizophrenia. An Updated Systematic Review
- EA 3279, CEReSS-Health Service Research and Quality of Life Center, School of Medicine-La Timone Medical, Aix-Marseille Université, AP-HM Assistance Publique des Hôpitaux de Marseille, Marseille, France
Objectives: The objective of this systematic review was to synthetize the published data on the relationships between elevated blood C-reactive protein (CRP) levels and schizophrenia (SZ) onset risk, illness characteristics and treatments, cognition and physical health.
Method: The systematic bibliographic searches have been carried out according to the Cochrane methodology. Medline, web of science, Google Scholar with each database being searched from inception to November 2017.
Results: 53 studies were included in the present review. While meta-analyses including case-control studies suggest a clear association between CRP and SZ, one other study has suggested that CRP-associated genes were associated with a lower risk of SZ onset. Increased CRP has been significantly associated with positive symptoms in acute phase psychosis, while studies including community-dwelling stabilized subjects did not find such an association. Abnormal CRP has been associated with a wide range of cognitive impairment in SZ stabilized individuals. Body Mass index has been extensively associated with increased CRP in SZ subjects; and increased CRP has been identified as a risk factor for metabolic syndrome and cardiovascular risk in SZ subjects. Increased CRP has also been associated with high nicotine dependence in SZ smokers and one study has suggested that increased CRP was associated with sedentary behavior.
Conclusion: In the light of the above-mentioned studies, increased hs-CRP may be reasonably suggested as a marker for SZ onset risk, as well as a risk factor for increased positive symptoms, cognitive impairment, hypovitaminosis D, microbiota disturbances, cardiovascular and metabolic syndrome risk in SZ subjects, and increased nicotine dependence in SZ smokers. In case of increased CRP levels, anti-inflammatory strategies (add-on anti-inflammatory drugs including aspirin and omega 3 fatty acids, vitamin D supplementation, physical activity, probiotics) should be also further evaluated.
Limits: Most of the studies were cross-sectional and cohort studies are needed to determine the temporal relationship between increased CRP and the psychiatric outcomes.
Inflammation is a complex physiologic response to injury or tissue destruction, and involves recruitment of immune cells. The inflammatory hypothesis of major psychiatric disorders, posits that inflammatory processes are involved in the pathogenesis of psychiatric conditions and may underpin some of their neurobiological correlates (1). SZ is the psychiatric disorder causing the most severe burden of illness for the individual, by its significant cognitive and social functioning impairments but also due to its medical comorbidities (2). A bundle of studies have suggested a link between inflammation and at least a subgroup of SZ subjects (1, 3–5).
C-reactive protein (CRP) is the most commonly used biomarker of systemic inflammation worldwide. CRP is a standard laboratory exam and can be measured in the peripheral blood and analyzed in any clinical laboratory around the globe. CRP is therefore a very attractive potential clinical biomarker in psychiatric disorders (6). CRP is an acute phase protein that is produced by hepatocytes. The high-sensitivity CRP (hs-CRP) assay has a lower limit of detection of 0.1 mg/L. The measurement of CRP is useful in the diagnosis and monitoring of many acute and chronic inflammatory conditions, including obesity and the metabolic syndrome, which can cause elevations of hs-CRP in the range of 3–10 mg/L (7). Increased CRP has been recently associated with cognitive impairment in SZ, which suggests that anti-inflammatory strategies may improve the debilitating course of this illness (8).
The objective of the present systematic review was to determine if dosing CRP blood levels was relevant to synthetize cross-sectional studies and to determine (i) SZ onset risk in general population (ii) clinical characteristics and treatments (iii) cognitive deficits and (iv) physical health in SZ in- and outpatients.
Materials and Methods
This meta-analysis is based on the PRISMA criteria (Preferred Reporting Items for Systematic reviews and Meta-Analysis). The systematic bibliographic searches have been carried out according to the Cochrane methodology. These were performed to find relevant English and non-English language trials from the following databases: Medline, web of science, Google Scholar with each database being searched from inception to November 2017. Medline is considered as the database of highest quality level, and google scholar as the database with the largest referencing of studies. Most of the international congress posters and abstracts are referenced in web of science. Altogether, these three searches enable a comprehensive exploration and limit the risk of publication bias. The associated articles were also explored, to limit the risk of bias associated with the search terms. The primary search strategy was “C-reactive protein” or “CRP” and “schizophrenia” or “ultra high risk psychosis.” Two reviewers (GF and LB) decided on eligibility and extracted data from included studies. The design of the studies, data extraction and data synthesis are described in Table 1. Only studies including at least a subgroup of SZ patients or at risk for SZ onset were included in the present review. As this meta-analysis mainly involved data from published studies, an institutional review board approval was not required.
Table 1. Studies exploring relationships between C-reactive protein (CRP) blood levels and schizophrenia (SZ): designs and major findings.
The study selection process is presented in Figure 1. Overall, 53 studies were included in the final qualitative analysis. The major findings and design characteristics of the included studies are presented in Table 1.
Schizophrenia Onset Risk
A recent meta-analysis including 18 studies (1,989 SZ vs. 3,689 healthy controls) has concluded that higher CRP levels were associated with increased risk of SZ, especially for young adult patients <30 years and independently of body mass index (9). Another recent meta-analysis has concluded that the association between elevated CRP and SZ was robust (1). These meta-analyses underlined that the difference between CRP levels of SZ subjects and HC were higher in young people (aged < 30), due to an increase of CRP in the HC group in older subjects and a stable increased CRP levels in SZ throughout the illness course, independently of administered treatments (1, 9).
A prospective study including 6,362 healthy adolescents ages 15–16 years has found that elevated CRP levels were predictive of SZ onset at age 27 (10). Elevated CRP in childhood has not been identified as predictive of psychotic disorder or SZ onset in adolescence in one prospective study including 4,500 children (11). One population-based prospective study has reported that elevated plasma CRP levels were associated with late-onset SZ (12).
Inconsistently with the previous findings, a large genetic study including >25,000 SZ subjects and >30,000 controls has concluded that alleles associated with increased CRP were protective from schizophrenia with a moderate effect (13).
Clinical Characteristics and Treatments
One recent meta-analysis has concluded that increased CRP levels were associated with positive but not negative symptoms in schizophrenia (1). However, many studies have reported no association between abnormal CRP levels and psychotic symptomatology (14–18). In one case control study, hsCRP levels were associated with insidious psychosis onset, duration of illness and chronic schizophrenia course with deterioration (17).
One study has found an association between current depression and abnormal CRP in SZ subjects (24) while another has found no association with depression but with antidepressant consumption (16). One study has found that history of childhood trauma was associated with increased CRP in SZ adulthood (25).
Abnormal CRP levels have been further associated with increased nicotine dependence in two studies (15, 26), but not with daily tobacco smoking (23). Abnormal CRP levels have been associated with increased aggressive behavior in SZ inpatients in one study (27) but this has not been replicated in one other SZ population (23). Increased CRP levels have been associated with impaired sensory gating in one small sample of stabilized SZ individuals (18).
The mean levels of CRP have not been found to change across the progression of the illness in one recent meta-analysis (1). While this meta-analysis has suggested that the antipsychotic treatment onset or modification did not impact mean peripheral CRP levels, one recent study has found that some specific psychotropic drugs were found to be associated with increased CRP levels (especially quetiapine, cyamemazine, tricyclic antidepressants, and hypnotics) independently of weight gain and tobacco smoking status (23). These results are consistent with the increased CRP levels in SZ subjects of the phase 1 CATIE study who received 3 months of quetiapine treatment (28). However, in the last study, the results have not been adjusted for weight gain. Inconsistent results have been found for olanzapine (23, 28). In one observational study and one clinical trial, aripiprazole has been found to be associated with decreased CRP blood levels (23, 29). The exact mechanism of the association of some psychotropic drugs and increased or decreased inflammation is not fully understood to date. Clozapine has been found to be associated with increased inflammation through mitochondria alterations and insulin resistance (30). Aripiprazole has been previously associated with lower rates of metabolic syndrome (31) and metabolic syndrome is one of the major sources of inflammation in SZ subjects (2). Only one study assessed the biological effect of the administration of a single dose of aripiprazole (10 mg) on the pro-inflammatory cytokine IL-6 blood levels with negative results in healthy volunteers (32). A recent study has shown that aripiprazole can suppress inflammatory responses triggered by Gram positive bacteria through suppression of both AP-1 and NF-κB pathways (33). Ziprasidone was found to trigger a macrophage inflammatory response in vitro (34). Quetiapine has been associated with high rates of constipation (35) and constipation may be associated with microbiota dysbiosis (36, 37). It may therefore be hypothesized that quetiapine-induced inflammation may be induced by intestinal local inflammation that may increase the intestinal barrier permeability. A recent study has found abnormal translocation bacterial markers in peripheral blood of SZ patients (38). Altogether, these results suggest that quetiapine may be associated with pro-inflammatory disturbances in SZ patients. Microbiota and gut permeability analyses are needed in future studies to determine the mechanisms of quetiapine-induced inflammation.
Abnormal CRP levels have been associated with impaired quality of life in SZ in one study (15). No association between increased CRP and impaired functioning in schizophrenia has been reported to date.
Abnormal CRP has been associated with a various range of impaired cognitive functions in both in/acute and out/stabilized SZ individuals (14, 16, 39, 40). More specifically, increased CRP levels have been associated with impaired short-term memory (39), impaired general intellectual ability and abstract reasoning, working memory, memory, learning abilities, semantic memory, mental flexibility, visual attention and speed of processing (8).
Increased CRP levels have been associated with all-causes mortality in SZ (41) and 10-years cardio-vascular disease risk (42). A study comparing 483 SZ and BD subjects to HCs has concluded that Trauma-altered immune activation via elevated hs-CRP in patients with SZ and BD may be mediated by higher BMI (25).
Increased CRP levels have been extensively associated with increased BMI and therefore metabolic syndrome and cardiovascular risk (3, 13, 15, 16, 20, 24, 28, 42–50). Increased CRP has been associated with decreased vitamin D blood level (51, 52), higher sedentary behavior (53), and increased markers of intestinal bacterial translocation (38).
The literature has yielded inconsistent results in regard of the links between elevated CRP levels and the risk of later SZ onset. The results of the Prins et al. study, suggesting that CRP-associated alleles were associated with decreased risk of SZ (13) have fueled the debate about whether the CRP elevation in SZ is a by-product of the pathogenesis of SZ or directly contributing to clinical features of the disorder. These findings may also point out potential biases in previous studies regarding the causes of elevated CRP levels in SZ patients, such as pleiotropic effects within chosen instruments and/or reverse causality (13). In addition to CRP variants, other recent studies have identified other variants associated with SZ including variants in the major histocompatibility complex region on Chromosome 6p21 (54), harboring many cytokine genes (55–57), and in the TNF promoter (58), IL10 promoter (59), IL1B (60) and C4 (61). To make a long story short, CRP has been robustly associated with the SZ risk, however it remains unclear if this association may be due to confounding factors. This association was independent of BMI, and history of childhood trauma has not been associated with SZ risk to date. However, tobacco smoking, increased gut permeability (38), infections [especially Toxoplasma (62), HSV virus (63) or HERV-W endoretrovirus (64), candida albicans (65)], sleep disturbances, dental care and periodontal diseases (66) and impaired physical activity (53) may be all confounding factors for this association. It should be underlined that increased CRP has been associated with social withdrawal in the general population, social withdrawal being one the prodromal symptoms of schizophrenia in adolescents (67, 68).
The discrepancies between studies suggesting that peripheral inflammation is associated with positive symptoms and the others may be due to the psychotic phase status of the included patients (i.e., acute psychosis vs. stabilized/community-dwelling subjects). The studies that found no association between increased CRP and symptomatology have recruited community-dwelling stabilized outpatients (16, 22, 23).
One study has found that history of childhood trauma was associated with increased CRP in SZ adulthood (25), however this result has not been replicated in other studies (16) and this association disappeared after adjustment for BMI.
Inconsistent findings have been found in regard of the association between abnormal CRP, current depression and antidepressant consumption in SZ, with one study suggesting that increased CRP levels were associated with depressive symptoms, and one other that it was associated with antidepressant consumption (16, 24). This discrepancy may be due to different antidepressant administration, as the different classes of antidepressant have been associated with various anti-inflammatory properties (69).
Daily tobacco smoking is a major issue in SZ patients, more than half being current tobacco smokers (70). Increased CRP has been associated with high nicotine (NIC) dependence in SZ subjects. This finding was not consistent with the hypothesis that NIC dependence would be associated with lower peripheral inflammation due to the in vitro anti-inflammatory effects of nicotine (71, 72). Due to the cross-sectional design of the study, a causal relationship could not be drawn. The results of this study may support the self-medication hypothesis of tobacco smoking in SZ, which is still currently debated (73–76). As such, SZ smokers with increased CRP may self-administer nicotine to limit the negative effects of peripheral inflammation. The hypothesis of a genetic shared vulnerability between chronic peripheral inflammation and NIC dependence may also be suggested and has been described in other psychiatric disorders (77). As increased CRP and NIC dependence have both been associated with cognitive impairment in SZ (8, 78), it remains also to be determined if inflammation mediates the association between NIC dependence and cognitive impairment in SZ smokers. Preclinical and clinical studies have indicated that 7 nAChR deregulation may account for some of the cognition and mood SZ symptoms, with NIC use representing a strategy to alleviate these symptoms (79). It remain unclear to date if increased CRP levels at baseline may be associated with an increase rate of tobacco use relapse in tobacco cessation programs, and if NIC substitutes administration may improve peripheral inflammation in SZ patients.
Increased CRP levels have been associated with a wide range of impaired cognitive functions. While many studies [for meta-analysis see (80)] have suggested that anti-inflammatory add-on therapy may be effective in SZ subjects, no study has explored to date if adding anti-inflammatory agents to conventional treatment may improve cognitive function in SZ subjects with cognitive deficits and inflammatory disturbances. Anti-inflammatory strategies, combined with cognitive remediation therapy and benzodiazepine withdrawal when needed, may be the most effective personalized-medicine approach to improve cognition in SZ subjects (81).
The physical health studies have confirmed that increased CRP levels was a predictor of metabolic syndrome and cardiovascular risk in SZ subjects (42, 46, 48–50). Increased CRP have been associated with decreased 25-OH vitamin D levels, which may suggest that supplementing vitamin D may improve inflammatory status and cardio-vascular risk in SZ subjects with hypovitaminosis D (51, 52). As sedentarily behavior has been associated with increased CRP levels (53), physical activity may be suggested as the prior therapeutic intervention for SZ subjects with increased weight and peripheral inflammation. As translocation markers have been associated with increased CRP (38), interventions for restoring the intestinal barrier integrity (namely probiotics and diet interventions) may be useful to improve inflammation status in SZ subjects with microbiota disturbances/ increased gut permeability and peripheral low-grade inflammation.
The risk of publication bias has been limited by the use of three databases, medline being considered as the database of reference with the highest quality studies, google scholar as the largest database, and web of science for exploring specific congress abstracts. Most of the included studies were cross-sectional. Because data on each participant are recorded only once it would be difficult to infer the temporal association between increased CRP and each explored outcome (82). Therefore, only an association, and not causation, can be inferred. These results may inform the hypotheses for a more complex investigation, such as a cohort study.
Some statistical approaches are commonly used to analyse CRP blood levels but they present some limits. The dichotomization of the variable using a cut-off raises the question of the (arbitrary) choice of this cut-off. No consensual cut-off values have been proposed in psychiatric studies for the analysis of CRP. A recent meta-analysis has pointed out that most of the included psychiatric studies used a cut-off ≥5 mg/L (3) while the international guidelines for predicting cardiovascular risk (“The Emerging Risk Factors Collaboration”; 2010) proposed a 3 mg/L cut-off. This last cut-off was also used in most of the psychiatric studies focusing on clinical symptoms and cognition. It remains unclear if these cut-offs, determined in non-psychiatric studies, are the most suitable for psychiatric studies. Moreover, the use of a dichotomized variable is questionable as it implies a loss of information (83). Considering CRP as a quantitative variable has led some researchers to use linear regression models. However, these models rely on the assumption of a normal distribution, which is not the case for CRP. It is possible to apply a log transformation of the data, which makes them more conform to normality (84). However, log transformation does not systematically help the data to be more normal or less variable (85, 86). Furthermore, log-transformed data cannot usually facilitate inferences concerning the original data, since it shares little in common with the original data (86). In the end, in the specific case of the CRP, the presence of a large number of patients with a value of 0 (undetectable) for the CRP makes this transformation impossible (0 values becoming –∞). In this context, the zero-inflated Poisson regression model may appear as the most suited statistical method, as it allows taking into account data which contain a substantial proportion of zero and with a highly skewed distribution, while keeping the whole of the information (87). This method has been used in only one study to date (23).
While sleep disorders have been suggested to have a bidirectional relationship with inflammation, no study has explored the relationships between abnormal CRP levels and sleep disorders in SZ to date. Except for antipsychotic effects, no longitudinal data has suggested if increased CRP levels were associated with poor prognosis and outcomes in schizophrenia (including hospitalizations, accelerated cognitive impairment and functioning). Further studies should explore if decreasing CRP blood levels may improve SZ outcomes, especially cardiometabolic events, tobacco smoking behavior, quality of life and cognitive functioning. As some add-on anti-inflammatory strategies have shown effectiveness in SZ symptomatology (88), each anti-inflammatory drug should be independently evaluated (especially omega 3 fatty acid and aspirin, which have been suggested to be effective in some SZ subgroups) (89, 90). As CRP is a global marker of inflammatory disturbances, the relationship between increased CRP and respectively oxidative stress disturbances and hormonal disturbances should also be explored and may lead to other therapeutic options, like N-acetyl-cysteine add-on administration (88).
In the light of the above-mentioned studies, increased hs-CRP may be reasonably suggested as a marker for SZ onset risk, as well as a risk factor for increased positive symptoms, cognitive impairment, hypovitaminosis D, microbiota disturbances, cardiovascular and metabolic syndrome risk in SZ subjects, and increased nicotine dependence in SZ smokers. In case of increased CRP levels, anti-inflammatory strategies (add-on anti-inflammatory drugs including aspirin and omega 3 fatty acids, vitamin D supplementation, physical activity, probiotics) should be further evaluated.
GF and LB selected the studies, analyzed the major outcomes and wrote the manuscript. CL and PA reviewed the manuscript. All authors approved the final version.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
This work was funded by Assistance Publique- Hôpitaux de Marseille. We express all our thanks to the patients who have participated to the studies presented in this article.
1. Fernandes BS, Steiner J, Bernstein H-G, Dodd S, Pasco JA, Dean OM, et al. C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications. Mol Psychiatry (2016) 21:554–64. doi: 10.1038/mp.2015.87
2. Godin O, Leboyer M, Gaman A, Aouizerate B, Berna F, Brunel L, et al. Metabolic syndrome, abdominal obesity and hyperuricemia in schizophrenia: results from the FACE-SZ cohort. Schizophr Res. (2015) 168:388–94. doi: 10.1016/j.schres.2015.07.047
4. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry (2008) 63:801–8. doi: 10.1016/j.biopsych.2007.09.024
5. Tourjman V, Kouassi É, Koué M-È, Rocchetti M, Fortin-Fournier S, Fusar-Poli P, et al. Antipsychotics' effects on blood levels of cytokines in schizophrenia: a meta-analysis. Schizophr Res. (2013) 151:43–7. doi: 10.1016/j.schres.2013.10.011
6. Fond G, d'Albis M-A, Jamain S, Tamouza R, Arango C, Fleischhacker WW, et al. The promise of biological markers for treatment response in first-episode psychosis: a systematic review. Schizophr Bull. (2015) 41:559–73. doi: 10.1093/schbul/sbv002
7. Windgassen EB, Funtowicz L, Lunsford TN, Harris LA, Mulvagh SL. C-reactive protein and high-sensitivity C-reactive protein: an update for clinicians. Postgrad Med. (2011) 123:114–9. doi: 10.3810/pgm.2011.01.2252
8. Bulzacka E, Boyer L, Schürhoff F, Godin O, Berna F, Brunel L, et al. Chronic peripheral inflammation is associated with cognitive impairment in schizophrenia: results from the multicentric FACE-SZ dataset. Schizophr Bull. (2016) 42:1290–302. doi: 10.1093/schbul/sbw029
10. Metcalf SA, Jones PB, Nordstrom T, Timonen M, Mäki P, Miettunen J, et al. Serum C-reactive protein in adolescence and risk of schizophrenia in adulthood: a prospective birth cohort study. Brain Behav Immun. (2017) 59:253–259. doi: 10.1016/j.bbi.2016.09.008
11. Khandaker GM, Pearson RM, Zammit S, Lewis G, Jones PB. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry (2014) 71:1121–8. doi: 10.1001/jamapsychiatry.2014.1332
12. Wium-Andersen MK, Ørsted DD, Nordestgaard BG. Elevated C-reactive protein associated with late- and very-late-onset schizophrenia in the general population: a prospective study. Schizophr Bull. (2014) 40:1117–27. doi: 10.1093/schbul/sbt120
13. Prins BP, Abbasi A, Wong A, Vaez A, Nolte I, Franceschini N, et al. Investigating the causal relationship of C-reactive protein with 32 complex somatic and psychiatric outcomes: a large-scale cross-consortium mendelian randomization study. PLoS Med. (2016) 13:e1001976. doi: 10.1371/journal.pmed.1001976
14. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res. (2007) 93:261–5. doi: 10.1016/j.schres.2007.03.022
15. Faugere M, Micoulaud-Franchi JA, Alessandrini M, Richieri R, Faget-Agius C, Auquier P, et al. Quality of life is associated with chronic inflammation in schizophrenia: a cross-sectional study. Sci Rep. (2015) 5:10793. doi: 10.1038/srep10793
16. Fond G, Godin O, Brunel L, Aouizerate B, Berna F, Bulzacka E, et al. Peripheral sub-inflammation is associated with antidepressant consumption in schizophrenia. Results from the multi-center FACE-SZ data set. J Affect Disord. (2016) 191:209–15. doi: 10.1016/j.jad.2015.11.017
17. Frydecka D, Misiak B, Pawlak-Adamska E, Karabon L, Tomkiewicz A, Sedlaczek P, et al. Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation. Eur Arch Psychiatry Clin Neurosci. (2015) 265:449–59. doi: 10.1007/s00406-014-0533-5
18. Micoulaud-Franchi J-A, Faugere M, Boyer L, Fond G, Richieri R, Faget C, et al. Elevated C-reactive protein is associated with sensory gating deficit in schizophrenia. Schizophr Res. (2015) 165:94–6. doi: 10.1016/j.schres.2015.03.018
19. Akanji AO, Ohaeri JU, Al-Shammri S, Fatania HR. Association of blood levels of C-reactive protein with clinical phenotypes in Arab schizophrenic patients. Psychiatry Res. (2009) 169:56–61. doi: 10.1016/j.psychres.2008.06.010
20. Joseph J, Depp C, Martin AS, Daly RE, Glorioso DK, Palmer BW, et al. Associations of high sensitivity C-reactive protein levels in schizophrenia and comparison groups. Schizophr Res. (2015) 168:456–60. doi: 10.1016/j.schres.2015.08.019
21. Wysokinski A, Margulska A, Strzelecki D, Kłoszewska I. Levels of C-reactive protein (CRP) in patients with schizophrenia, unipolar depression and bipolar disorder. Nord J Psychiatry (2015) 69:346–53. doi: 10.3109/08039488.2014.984755
23. Fond G, Resseguier N, Schürhoff F, Godin O, Andrianarisoa M, Brunel L, et al. Relationships between low-grade peripheral inflammation and psychotropic drugs in schizophrenia: results from the national FACE-SZ cohort. Eur Arch Psychiatry Clin Neurosci. (2017). 268:541–53. doi: 10.1007/s00406-017-0847-1
24. Faugere M, Micoulaud-Franchi J-A, Faget-Agius C, Lançon C, Cermolacce M, Richieri R. High C-reactive protein levels are associated with depressive symptoms in schizophrenia. J Affect Disord. (2018) 225:671–5. doi: 10.1016/j.jad.2017.09.004
25. Aas M, Dieset I, Hope S, Hoseth E, Mørch R, Reponen E, et al. Childhood maltreatment severity is associated with elevated C-reactive protein and body mass index in adults with schizophrenia and bipolar diagnoses. Brain Behav Immun. (2017) 65:342–9. doi: 10.1016/j.bbi.2017.06.005
26. Fond G, Berna F, Andrianarisoa M, Godin O, Leboyer M, Brunel L, et al. Chronic low-grade peripheral inflammation is associated with severe nicotine dependence in schizophrenia: results from the national multicentric FACE-SZ cohort. Eur Arch Psychiatry Clin Neurosci. (2017) 267:465–72. doi: 10.1007/s00406-017-0771-4
27. Barzilay R, Lobel T, Krivoy A, Shlosberg D, Weizman A, Katz N. Elevated C-reactive protein levels in schizophrenia inpatients is associated with aggressive behavior. Eur Psychiatry (2016) 31:8–12. doi: 10.1016/j.eurpsy.2015.09.461
28. Meyer JM, McEvoy JP, Davis VG, Goff DC, Nasrallah HA, Davis SM, et al. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biol Psychiatry (2009) 66:1013–22. doi: 10.1016/j.biopsych.2009.06.005
29. Sobiś J, Rykaczewska-Czerwinska M, Swietochowska E, Gorczyca P. Therapeutic effect of aripiprazole in chronic schizophrenia is accompanied by anti-inflammatory activity. Pharmacol Rep. (2015) 67:353–9. doi: 10.1016/j.pharep.2014.09.007
30. Contreras-Shannon V, Heart DL, Paredes RM, Navaira E, Catano G, Maffi SK, et al. Clozapine-induced mitochondria alterations and inflammation in brain and insulin-responsive cells. PLoS ONE (2013) 8:e59012. doi: 10.1371/journal.pone.0059012
32. Handley R, Mondelli V, Zelaya F, Marques T, Taylor H, Reinders AATS, et al. Effects of antipsychotics on cortisol, interleukin-6 and hippocampal perfusion in healthy volunteers. Schizophr Res. (2016). 174:99–105. doi: 10.1016/j.schres.2016.03.039
34. Duarte T, Barbisan F, do Prado-Lima PAS, Azzolin VF, da Cruz Jung IE, Duarte MMMF, et al. Ziprasidone, a second-generation antipsychotic drug, triggers a macrophage inflammatory response in vitro. Cytokine (2017). 106:101–7. doi: 10.1016/j.cyto.2017.10.017
35. Maneeton N, Maneeton B, Woottiluk P, Likhitsathian S, Suttajit S, Boonyanaruthee V, et al. Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. (2016) 10:259–76. doi: 10.2147/DDDT.S89485
36. Chassard C, Dapoigny M, Scott KP, Crouzet L, Del'homme C, Marquet P, et al. Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. Aliment Pharmacol Ther. (2012) 35:828–38. doi: 10.1111/j.1365-2036.2012.05007.x
37. Zoppi G, Cinquetti M, Luciano A, Benini A, Muner A, Bertazzoni Minelli E. The intestinal ecosystem in chronic functional constipation. Acta Paediatr. (1998) 87:836–41. doi: 10.1111/j.1651-2227.1998.tb01547.x
38. Severance EG, Gressitt KL, Stallings CR, Origoni AE, Khushalani S, Leweke FM, et al. Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia. Schizophr Res. (2013) 148:130–7. doi: 10.1016/j.schres.2013.05.018
39. Dorofeikova M, Neznanov N, Petrova N. Cognitive deficit in patients with paranoid schizophrenia: Its clinical and laboratory correlates. Psychiatry Res. (2017). 262:542–8. doi: 10.1016/j.psychres.2017.09.041
40. Johnsen E, Fathian F, Kroken RA, Steen VM, Jørgensen HA, Gjestad R, et al. The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis. BMC Psychiatry (2016) 16:60. doi: 10.1186/s12888-016-0769-x
41. Horsdal HT, Köhler-Forsberg O, Benros ME, Gasse C. C-reactive protein and white blood cell levels in schizophrenia, bipolar disorders and depression–associations with mortality and psychiatric outcomes: a population-based study. Eur Psychiatry (2017) 44:164–72. doi: 10.1016/j.eurpsy.2017.04.012
42. Sicras-Mainar A, Rejas-Gutiérrez J, Navarro-Artieda R, Blanca-Tamayo M. C-reactive protein as a marker of cardiovascular disease in patients with a schizophrenia spectrum disorder treated in routine medical practice. Eur Psychiatry (2013) 28:161–7. doi: 10.1016/j.eurpsy.2011.07.003
43. Balõtšev R, Koido K, Vasar V, Janno S, Kriisa K, Mahlapuu R, et al. Inflammatory, cardio-metabolic and diabetic profiling of chronic schizophrenia. Eur Psychiatry (2017) 39:1–10. doi: 10.1016/j.eurpsy.2016.05.010
44. Klemettilä J-P, Kampman O, Seppälä N, Viikki M, Hämäläinen M, Moilanen E, et al. Resistin as an inflammatory marker in patients with schizophrenia treated with clozapine. Nord J Psychiatry (2017) 71:89–95. doi: 10.1080/08039488.2016.1230649
45. Miller BJ, Mellor A, Buckley P. Total and differential white blood cell counts, high-sensitivity C-reactive protein, and the metabolic syndrome in non-affective psychoses. Brain Behav Immun. (2013) 31:82–9. doi: 10.1016/j.bbi.2012.08.016
46. Mori N, McEvoy JP, Miller BJ. Total and differential white blood cell counts, inflammatory markers, adipokines, and the metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Schizophr Res. (2015) 169:30–5. doi: 10.1016/j.schres.2015.10.001
47. Suvisaari J, Loo B-M, Saarni SE, Haukka J, Perälä J, Saarni SI, et al. Inflammation in psychotic disorders: a population-based study. Psychiatry Res. (2011) 189:305–11. doi: 10.1016/j.psychres.2011.07.006
48. Dieset I, Hope S, Ueland T, Bjella T, Agartz I, Melle I, et al. Cardiovascular risk factors during second generation antipsychotic treatment are associated with increased C-reactive protein. Schizophr Res. (2012) 140:169–74. doi: 10.1016/j.schres.2012.06.040
49. Popović I, Ravanić D, Janković S, Milovanović D, Folić M, Stanojević A, et al. Long-term treatment with olanzapine in hospital conditions: prevalence and predictors of the metabolic syndrome. Srp Arh Celok Lek. (2015) 143:712–8. doi: 10.2298/SARH1512712P
51. Lally J, Gardner-Sood P, Firdosi M, Iyegbe C, Stubbs B, Greenwood K, et al. Clinical correlates of vitamin D deficiency in established psychosis. BMC Psychiatry (2016) 16:76. doi: 10.1186/s12888-016-0780-2
52. Zhu D, Liu Y, Zhang A, Chu Z, Wu Q, Li H, et al. High levels of vitamin D in relation to reduced risk of schizophrenia with elevated C-reactive protein. Psychiatry Res. (2015) 228:565–70. doi: 10.1016/j.psychres.2015.05.051
53. Stubbs B, Gardner-Sood P, Smith S, Ismail K, Greenwood K, Farmer R, et al. Sedentary behaviour is associated with elevated C-reactive protein levels in people with psychosis. Schizophr Res. (2015) 168:461–4. doi: 10.1016/j.schres.2015.07.003
54. Lewis CM, Levinson DF, Wise LH, DeLisi LE, Straub RE, Hovatta I, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. Am J Hum Genet. (2003) 73:34–48. doi: 10.1086/376549
55. International Schizophrenia Consortium, Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature (2009) 460:748–52. doi: 10.1038/nature08185
58. Saviouk V, Chow EWC, Bassett AS, Brzustowicz LM. Tumor necrosis factor promoter haplotype associated with schizophrenia reveals a linked locus on 1q44. Mol Psychiatry (2005) 10:375–83. doi: 10.1038/sj.mp.4001582
59. Al-Asmary SM, Kadasah S, Arfin M, Tariq M, Al-Asmari A. Genetic variants of interleukin-10 gene promoter are associated with schizophrenia in Saudi patients: a case-control study. N Am J Med Sci. (2014) 6:558–65. doi: 10.4103/1947-2714.145466
60. Hänninen K, Katila H, Saarela M, Rontu R, Mattila KM, Fan M, et al. Interleukin-1 beta gene polymorphism and its interactions with neuregulin-1 gene polymorphism are associated with schizophrenia. Eur Arch Psychiatry Clin Neurosci. (2008) 258:10–5. doi: 10.1007/s00406-007-0756-9
61. Sekar, A,. A Natural Allelic Series of Complex Structural Variants and its Influence on the Risk of Lupus and Schizophrenia. Available online at: https://dash.harvard.edu/handle/1/13070061 (Accessed December 26, 2017).
62. Sutterland AL, Fond G, Kuin A, Koeter MWJ, Lutter R, van Gool T, et al. Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta-analysis. Acta Psychiatr Scand. (2015). 132:161–79. doi: 10.1111/acps.12423
63. Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yolken R. Additive effects of elevated C-reactive protein and exposure to herpes simplex virus type 1 on cognitive impairment in individuals with schizophrenia. Schizophr Res. (2012) 134:83–8. doi: 10.1016/j.schres.2011.10.003
64. Perron H, Mekaoui L, Bernard C, Veas F, Stefas I, Leboyer M. Endogenous retrovirus type W GAG and envelope protein antigenemia in serum of schizophrenic patients. Biol Psychiatry (2008) 64:1019–23. doi: 10.1016/j.biopsych.2008.06.028
65. Severance EG, Gressitt KL, Stallings CR, Katsafanas E, Schweinfurth LA, Savage CL, et al. Candida albicans exposures, sex specificity and cognitive deficits in schizophrenia and bipolar disorder. NPJ Schizophr. (2016) 2:16018. doi: 10.1038/npjschz.2016.18
66. Berk M, Williams LJ, Jacka FN, O'Neil A, Pasco JA, Moylan S, et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med. (2013) 11:200. doi: 10.1186/1741-7015-11-200
68. Vedhara K, Gill S, Eldesouky L, Campbell BK, Arevalo JMG, Ma J, et al. Personality and gene expression: do individual differences exist in the leukocyte transcriptome? Psychoneuroendocrinology (2015) 52:72–82. doi: 10.1016/j.psyneuen.2014.10.028
69. Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology (2011) 36:2452–9. doi: 10.1038/npp.2011.132
70. Rey R, D'Amato T, Boyer L, Brunel L, Aouizerate B, Berna F, et al. Nicotine dependence is associated with depression and childhood trauma in smokers with schizophrenia: results from the FACE-SZ dataset. Eur Arch Psychiatry Clin Neurosci. (2017). 267:567–77. doi: 10.1007/s00406-017-0779-9.
71. Báez-Pagán CA, Delgado-Vélez M, Lasalde-Dominicci JA. Activation of the macrophage α7 nicotinic acetylcholine receptor and control of inflammation. J Neuroimmune Pharmacol. (2015) 10:468–76. doi: 10.1007/s11481-015-9601-5
73. Amitai N, Markou A. Chronic nicotine improves cognitive performance in a test of attention but does not attenuate cognitive disruption induced by repeated phencyclidine administration. Psychopharmacology (Berl). (2009) 202:275–86. doi: 10.1007/s00213-008-1246-0
75. Drusch K, Lowe A, Fisahn K, Brinkmeyer J, Musso F, Mobascher A, et al. Effects of nicotine on social cognition, social competence and self-reported stress in schizophrenia patients and healthy controls. Eur Arch Psychiatry Clin Neurosci. (2013) 263:519–27. doi: 10.1007/s00406-012-0377-9
76. Hahn B, Harvey AN, Concheiro-Guisan M, Huestis MA, Holcomb HH, Gold JM. A test of the cognitive self-medication hypothesis of tobacco smoking in schizophrenia. Biol Psychiatry (2013) 74:436–43. doi: 10.1016/j.biopsych.2013.03.017
77. Nunes SOV, Vargas HO, Prado E, Barbosa DS, de Melo LP, Moylan S, et al. The shared role of oxidative stress and inflammation in major depressive disorder and nicotine dependence. Neurosci Biobehav Rev. (2013) 37:1336–45. doi: 10.1016/j.neubiorev.2013.04.014
79. Parikh V, Kutlu MG, Gould TJ. nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: current trends and perspectives. Schizophr Res. (2016) 171:1–15. doi: 10.1016/j.schres.2016.01.020
80. Sommer IE, van Westrhenen R, Begemann MJ, de Witte LD, Leucht S, Kahn RS. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull. (2013). 40:181–91. doi: 10.1093/schbul/sbt139
81. Fond G, Berna F, Boyer L, Godin O, Brunel L, Andrianarisoa M, et al. Benzodiazepine long-term administration is associated with impaired attention/working memory in schizophrenia: results from the national multicentre FACE-SZ data set. Eur Arch Psychiatry Clin Neurosci. (2017) 268:17–26. doi: 10.1007/s00406-017-0787-9
87. Atkins DC, Baldwin SA, Zheng C, Gallop RJ, Neighbors C. A tutorial on count regression and zero-altered count models for longitudinal substance use data. Psychol Addict Behav. (2013) 27:166–77. doi: 10.1037/a0029508
88. Fond G, Hamdani N, Kapczinski F, Boukouaci W, Drancourt N, Dargel A, et al. Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review. Acta Psychiatr Scand. (2014) 129:163–79. doi: 10.1111/acps.12211
89. Kidd PM. Omega-3 DHA and EPA for cognition, behavior, and mood: clinical findings and structural-functional synergies with cell membrane phospholipids. Altern Med Rev J Clin Ther. (2007) 12:207–27.
90. Nitta M, Kishimoto T, Müller N, Weiser M, Davidson M, Kane JM, et al. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr Bull. (2013) 39:1230–41. doi: 10.1093/schbul/sbt070
Keywords: C-reactive protein (CRP), schizophrenia, peripheral biomarker, onset risk, cognition, physical health, nicotine dependence
Citation: Fond G, Lançon C, Auquier P and Boyer L (2018) C-Reactive Protein as a Peripheral Biomarker in Schizophrenia. An Updated Systematic Review. Front. Psychiatry 9:392. doi: 10.3389/fpsyt.2018.00392
Received: 08 January 2018; Accepted: 06 August 2018;
Published: 23 August 2018.
Edited by:Dorota Frydecka, Wroclaw Medical University, Poland
Reviewed by:Elena Martín-García, Universidad Pompeu Fabra, Spain
Carolina Haass-Koffler, Brown University, United States
Copyright © 2018 Fond, Lançon, Auquier and Boyer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Guillaume Fond, email@example.com